Literature DB >> 11684440

Hypoxia: the tumor's gateway to progression along the angiogenic pathway.

C Brahimi-Horn1, E Berra, J Pouysségur.   

Abstract

Decreased aerobic (hypoxic) conditions in tumors induce the release of cytokines that promote vascularization and thereby enhance tumor growth and metastasis. Recent major advances have provided insight into the role hypoxia plays in cancer biology. The domain structure of the hypoxia-inducible factor 1alpha (HIF-1alpha) has been elucidated, as has the mechanism by which stabilization of HIF-1alpha leads to initiation of the transcription of target genes involved in growth of blood vessels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684440     DOI: 10.1016/s0962-8924(01)02126-2

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  28 in total

1.  A spatial model of tumor-host interaction: application of chemotherapy.

Authors:  Peter Hinow; Philip Gerlee; Lisa J McCawley; Vito Quaranta; Madalina Ciobanu; Shizhen Wang; Jason M Graham; Bruce P Ayati; Jonathan Claridge; Kristin R Swanson; Mary Loveless; Alexander R A Anderson
Journal:  Math Biosci Eng       Date:  2009-07       Impact factor: 2.080

2.  Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.

Authors:  Daniel Escuin; Erik R Kline; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

3.  Differential growth inhibition of cerebral metastases by anti-angiogenic compounds.

Authors:  Daniel K Martin; Ortrud Uckermann; Aiko Bertram; Corina Liebner; Sandy Hendruschk; Kerim Hakan Sitoci-Ficici; Gabriele Schackert; Edith M Lord; Achim Temme; Matthias Kirsch
Journal:  Anticancer Res       Date:  2014-07       Impact factor: 2.480

4.  Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes.

Authors:  Claudine Kieda; Ruth Greferath; Claire Crola da Silva; Konstantina C Fylaktakidou; Jean-Marie Lehn; Claude Nicolau
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-06       Impact factor: 11.205

5.  Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells.

Authors:  Caroline Muir; Leland W K Chung; Daniel D Carson; Mary C Farach-Carson
Journal:  Clin Exp Metastasis       Date:  2006-07-07       Impact factor: 5.150

6.  Double knockdown of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances stem cell mobilization and angiogenesis after myocardial infarction.

Authors:  Mei Huang; Patricia Nguyen; Fangjun Jia; Shijun Hu; Yongquan Gong; Patricia E de Almeida; Li Wang; Divya Nag; Mark A Kay; Amato J Giaccia; Robert C Robbins; Joseph C Wu
Journal:  Circulation       Date:  2011-09-13       Impact factor: 29.690

7.  Short hairpin RNA interference therapy for ischemic heart disease.

Authors:  Mei Huang; Denise A Chan; Fangjun Jia; Xiaoyan Xie; Zongjin Li; Grant Hoyt; Robert C Robbins; Xiaoyuan Chen; Amato J Giaccia; Joseph C Wu
Journal:  Circulation       Date:  2008-09-30       Impact factor: 29.690

Review 8.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

9.  HIF-1alpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia.

Authors:  Ying Dai; Meifeng Xu; Yigang Wang; Zeeshan Pasha; Tingyu Li; Muhammad Ashraf
Journal:  J Mol Cell Cardiol       Date:  2007-04-06       Impact factor: 5.000

10.  Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.

Authors:  José Miguel Jurado; José Miguel Jurado García; Alfonso Sánchez; Bella Pajares; Elisabeth Pérez; Lorenzo Alonso; Emilio Alba
Journal:  Clin Transl Oncol       Date:  2008-09       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.